Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Tobias Neef, Stephen D. Miller*

*Corresponding author for this work

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Purpose of Review: The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases are typically treated with broad immunosuppression, but this has multiple disadvantages. Induction of antigen-specific tolerance is preferable. The application of nanomedicine to the problem of T1D can take different forms, but one promising way is the development of tolerogenic nanoparticles, the aim of which is to mitigate the islet-destroying autoimmunity. We review the topic and highlight recent strategies to produce tolerogenic nanoparticles for the purpose of treating T1D. Recent Findings: Several groups are making progress in applying tolerogenic nanoparticles to rodent models of T1D, while others are using nanotechnology to aid other potential T1D treatments such as islet transplant and islet encapsulation. Summary: The strategies behind how nanoparticles achieve tolerance are varied. It is likely the future will see even greater diversity in tolerance induction strategies as well as a greater focus on how to translate this technology from preclinical use in mice to treatment of T1D in humans.

Original languageEnglish (US)
Article number84
JournalCurrent diabetes reports
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 1 2017

    Fingerprint

Keywords

  • Diabetogenic antigens
  • PLG nanoparticles
  • Regulatory T cells
  • Tolerance
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this